Patents by Inventor Filip S. EKHOLM
Filip S. EKHOLM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11723983Abstract: The invention relates to a glycoprotein-toxic pay-load molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composi-tion. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tu-mour cells.Type: GrantFiled: March 23, 2021Date of Patent: August 15, 2023Assignee: GLYKOS FINLAND OYInventors: Tero Satomaa, Jari Helin, Filip S. Ekholm
-
Publication number: 20210252158Abstract: The invention relates to a glycoprotein-toxic pay-load molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical compos-ition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tu-mour cells.Type: ApplicationFiled: March 23, 2021Publication date: August 19, 2021Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM
-
Publication number: 20210106692Abstract: The present invention relates to a conjugate represented by the formula [D-L-Y—(CH2)n-]mP-T wherein T is a protein; P is a polymer selected from the group consisting of dextran, mannan, pullulan, hyaluronic acid, hydroxyethyl starch, chondroitin sulphate, heparin, heparin sulphate, polyalkylene glycol, Ficoll, polyvinyl alcohol, amylose, amylopectin, chitosan, cyclodextrin, pectin and carrageenan, or a derivative thereof; m is at least 1; n is in the range of 1 to 10; each Y is independently selected from the group consisting of S, NH and 1,2,3-triazolyl, wherein 1,2,3-triazolyl is optionally substituted; each L is independently absent or comprises a linker group covalently joining D and Y; and each D is a payload molecule.Type: ApplicationFiled: September 22, 2020Publication date: April 15, 2021Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Filip S. Ekholm, Anne Leppanen
-
Publication number: 20210106689Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.Type: ApplicationFiled: November 4, 2020Publication date: April 15, 2021Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
-
Patent number: 10973920Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.Type: GrantFiled: June 26, 2015Date of Patent: April 13, 2021Assignee: GLYKOS FINLAND OYInventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
-
Patent number: 10973922Abstract: The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.Type: GrantFiled: September 14, 2017Date of Patent: April 13, 2021Assignee: Glykos Finland OYInventors: Tero Satomaa, Jari Helin, Filip S. Ekholm
-
Patent number: 10835606Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)”—S—Bi2Hii2? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: GrantFiled: April 15, 2019Date of Patent: November 17, 2020Assignee: Tenboron OyInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Publication number: 20190240330Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)”—S—Bi2Hii2? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: ApplicationFiled: April 15, 2019Publication date: August 8, 2019Applicant: Tenboron OyInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Patent number: 10328149Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)n—S—B12H112? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: GrantFiled: June 12, 2015Date of Patent: June 25, 2019Assignee: TENBORON OYInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Publication number: 20180256732Abstract: The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.Type: ApplicationFiled: September 14, 2017Publication date: September 13, 2018Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM
-
Publication number: 20180228906Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.Type: ApplicationFiled: June 26, 2015Publication date: August 16, 2018Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
-
Publication number: 20170189549Abstract: The present invention relates to a conjugate represented by the formula [D-L-Y—(CH2)n-O]m—P-T wherein T is a protein; P is a polymer selected from the group consisting of dextran, mannan, pullulan, hyaluronic acid, hydroxyethyl starch, chondroitin sulphate, heparin, heparin sulphate, polyalkylene glycol, Ficoll, polyvinyl alcohol, amylose, amylopectin, chitosan, cyclodextrin, pectin and carrageenan, or a derivative thereof; m is at least 1; n is in the range of 1 to 10; each Y is independently selected from the group consisting of S, NH and 1,2,3-triazolyl, wherein 1,2,3-triazolyl is optionally substituted; each L is independently absent or comprises a linker group covalently joining D and Y; and each D is a payload molecule.Type: ApplicationFiled: June 12, 2015Publication date: July 6, 2017Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Filip S. Ekholm, Anne Leppanen
-
Publication number: 20170112931Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)n—S—B12H112? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: ApplicationFiled: June 12, 2015Publication date: April 27, 2017Applicant: Tenboron OyInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Publication number: 20160106860Abstract: The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.Type: ApplicationFiled: May 2, 2014Publication date: April 21, 2016Inventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM
-
Publication number: 20150314007Abstract: The invention relates to novel linker-payload molecule conjugates. The invention also relates to novel cell binder-linker-payload molecule conjugates, in particular antibody conjugates of dolastatin or auristatin derivatives.Type: ApplicationFiled: December 20, 2013Publication date: November 5, 2015Applicant: Glykos Finland OyInventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM, Henna PYNNÖNEN